Volume 12 Number 11/12 November/December 2011

13th European AIDS Conference (EACS), Belgrade, Serbia, 12-15 October 2011

European guidelines (EACS) – 2011 update

Raltegravir achieves superiority over efavirenz after four years

Higher plasma levels of tenofovir and darunavir but not efavirenz in older patients

Ritonavir levels reduced with high fat meal

Transplacental transfer of raltegravir and delayed plasma clearance in preterm neonates

2nd International Workshop on HIV and Ageing, Baltimore, Maryland, 27-28 October 2011

Statin blocks negative impact of PIs on bone formation in vitro

HIV linked to frailty in middle-aged IDUs, especially with poor HIV control

51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Chicago, 17-20 September 2011

Monitoring kidney function change with cobicistat

Intracellular raltegravir concentrations better with twice-daily than once-daily dosing

Rilpivirine (Edurant) and rilpivirine/FTC/tenofovir FDC (Eviplera) approved in Europe

FDA updates US label for darunavir for serious rash

FDA updates US label for raltegravir due to serious rash

Lopinavir concentrations suboptimal at reduced dose of lopinavir/ritonavir 200/50 mg twice daily

Switching to 50mg ritonavir dose for selected protease inhibitors

New formulations, acquisitions and company announcements

Iranian doctors now freed

New York court rejects AIDS denialist case against leading HIV community activist and journalist

UK ban on HIV-positive doctors and dentists set to be overturned

We Were Here

US guidelines (DHHS) update recommendations for first-line combinations (October 2011)

Global Fund cancels Round 11 and introduces new rules for grant renewals

Cure research: report from research workshop

Free full text online articles

FDA approval of generic ARVs

We need the Patent Pool to work

Efavirenz under-dosing in children

Treatment response and duration of first line treatment in European infants

US guidelines for management of older people living with HIV (2011)

New studies on HIV and the diseases of ageing

Risk of cataract surgery higher in HIV positive compared to HIV negative people

CD4 count <200 independently associated with 5-fold increased risk of fracture

Exercise as immune-based therapy

Mapping the long genetic road to broadly neutralising antibodies

Monkey viral reservoir study goes for gold

Immune pressure on HIV

Lymphocyte production capacity in HIV: links to immune activation & immune reconstitution on ART

International PrEP study (VOICE) discontinues use of tenofovir vaginal gel due to lack of efficacy

UK Health Protection Agency (HPA) recommends universal HIV testing in the high incidence regions of the UK

Volume 12 Number 11/12 November/December 2011 PDF

6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 17-20 July 2011, Rome

Cure research and viral reservoirs

Orange Farm circumcision results dispel concerns about risk compensation

Randomised trial of ART in TB patients with high CD4 counts

Once-daily nevirapine approved in Europe

Fixed-dose combination of rilpivirine/tenofovir/FTC (Eviplera) recommended for approval in Europe

ViiV withdraw European application for once-daily maraviroc

FDA approval of generic ARVs

Increased risk of preterm delivery with protease inhibitor based HAART in Mma Bana

Global Fund adopts restructuring recommendations and close to 50% funding shortfall for next round of grants

Efavirenz in pregnancy: update of systemic review and meta-analysis

AZT not equivalent to HAART to prevent mother-to-child transmission in a Botswana programme

Increased risk of HIV transmission to HIV negative partners during pregnancy

Pharmacokinetics of paediatric tenofovir based regimens

Atazanavir pharmacokinetics in infants, children and adolescents

Crushing lopinavir/ritonavir tablets decreases exposure by almost half in children

WHO Guidelines on guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

IPT for adults: Should the Mantoux test have been removed from WHO guidelines?

DSMB stops oral tenofovir monotherapy arm of VOICE PrEP study due to lack of difference compared to placebo

i-Base phoneline and information request services: review of service use: 2004-2011

Job vacancy: i-Base administrator

Volume 12 Number 9/10 September/October 2011 PDF

Post navigation